Zimmer Biomet Holdings, Inc. (ZBH) Analysts See $2.10 EPS

January 12, 2018 - By Jan Rainey

 Zimmer Biomet Holdings, Inc. (ZBH) Analysts See $2.10 EPS

Analysts expect Zimmer Biomet Holdings, Inc. (NYSE:ZBH) to report $2.10 EPS on January, 30.They anticipate $0.04 EPS change or 1.87 % from last quarter’s $2.14 EPS. ZBH’s profit would be $425.19M giving it 14.56 P/E if the $2.10 EPS is correct. After having $1.72 EPS previously, Zimmer Biomet Holdings, Inc.’s analysts see 22.09 % EPS growth. The stock decreased 0.20% or $0.24 during the last trading session, reaching $122.29. About 1.30M shares traded. Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has declined 0.44% since January 12, 2017 and is downtrending. It has underperformed by 17.14% the S&P500.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Ratings Coverage

Among 30 analysts covering Zimmer Biomet Holdings (NYSE:ZBH), 22 have Buy rating, 1 Sell and 7 Hold. Therefore 73% are positive. Zimmer Biomet Holdings had 82 analyst reports since August 27, 2015 according to SRatingsIntel. The rating was upgraded by Deutsche Bank to “Buy” on Tuesday, November 14. The firm has “Buy” rating by Zacks given on Friday, August 28. The firm has “Buy” rating given on Thursday, October 26 by Needham. The firm earned “Buy” rating on Friday, August 25 by RBC Capital Markets. The firm has “Neutral” rating given on Tuesday, August 2 by UBS. The rating was initiated by UBS on Tuesday, September 22 with “Neutral”. Needham maintained Zimmer Biomet Holdings, Inc. (NYSE:ZBH) rating on Tuesday, December 19. Needham has “Buy” rating and $144.0 target. The firm earned “Overweight” rating on Friday, April 29 by Barclays Capital. The firm earned “Neutral” rating on Thursday, November 2 by PiperJaffray. The stock of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) earned “Buy” rating by BMO Capital Markets on Tuesday, December 12.

Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, makes, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company has market cap of $24.76 billion. It operates through four divisions: Americas Spine, Office Based Technologies, Craniomaxillofacial and Thoracic , and Dental. It has a 38.19 P/E ratio. The firm provides orthopedic reconstructive products, such as knee and hip reconstructive products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

More notable recent Zimmer Biomet Holdings, Inc. (NYSE:ZBH) news were published by: Prnewswire.com which released: “Zimmer Biomet Announces Publication of Positive Results from PROGRESS II Trial …” on December 22, 2017, also Prnewswire.com with their article: “Zimmer Biomet Announces Appointment of Bryan C. Hanson as President and Chief …” published on December 19, 2017, Nasdaq.com published: “FDA Nod for Zimmer Biomet’s Sidus, Aids Arthroplasty Arm” on January 08, 2018. More interesting news about Zimmer Biomet Holdings, Inc. (NYSE:ZBH) were released by: Prnewswire.com and their article: “Zimmer Biomet Announces FDA Clearance of the Sidus® Stem-Free Shoulder System” published on January 03, 2018 as well as Fool.com‘s news article titled: “Why Darden Restaurants, Zimmer Biomet Holdings, and Applied Optoelectronics …” with publication date: December 19, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.